FDA approves wireless insulin pen
A new diabetes care device has been approved by the U.S. Food and Drug Administration this week, marking an advancement in how diabetics can manage their insulin consumption using technology.
The InPen, manufactured by Companion Medical, is a wireless-enabled insulin pen and proprietary mobile application that can calculate and recommend insulin dosing, track dosage history, monitor insulin temperature and track and report activity to a healthcare provider, the company said in a statement.
Companion, based in San Diego, specializes in manufacturing diabetic care devices.
The InPen has been cleared to be used with Lilly Humalog and Novo Nordisk Novolog rapid acting insulin and is compatible with Apple iOS. An Android version is planned to be released later this year.
"FDA clearance of the InPen and mobile app represents a significant advancement in diabetes care," said Sean Saint, CEO of Companion, in a statement. "The product combines the benefits of sophisticated insulin pumps with the simplicity and affordability of pens and syringes, providing patients, physicians, and caregivers increased confidence that diabetes is being managed optimally.”
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.